The skeletal cell‐derived molecule sclerostin drives bone marrow adipogenesis. Issue 2 (6th June 2017)

• Record Type: Journal Article
• Authors: Fairfield, Heather; Falank, Carolyne; Harris, Elizabeth; Demambro, Victoria; McDonald, Michelle; Pettitt, Jessica A.; Mohanty, Sindhu T.; Croucher, Peter; Kramer, Ina; Kneissel, Michaela; Rosen, Clifford J.; Reagan, Michaela R.
• Is Part Of: Journal of cellular physiology. Volume 233:Issue 2(2018:Feb.)
• Page Start: 1156
• Page End: 1167
• Publication Date: 2017-06-06
• Subjects: bone marrow adipose -- bone marrow microenvironment -- osteocyte‐derived factors -- sclerostin; Physiology -- Periodicals; Cell physiology -- Periodicals; 571.6
• DOI: 10.1002/jcp.25976
• Languages: English
• ISSNs: 0021-9541

Abstract

Abstract : The bone marrow niche is a dynamic and complex microenvironment that can both regulate, and be regulated by the bone matrix. Within the bone marrow (BM), mesenchymal stromal cell (MSC) precursors reside in a multi‐potent state and retain the capacity to differentiate down osteoblastic, adipogenic, or chondrogenic lineages in response to numerous biochemical cues. These signals can be altered in various pathological states including, but not limited to, osteoporotic‐induced fracture, systemic adiposity, and the presence of bone‐homing cancers. Herein we provide evidence that signals from the bone matrix (osteocytes) determine marrow adiposity by regulating adipogenesis in the bone marrow. Specifically, we found that physiologically relevant levels of Sclerostin (SOST), which is a Wnt‐inhibitory molecule secreted from bone matrix‐embedded osteocytes, can induce adipogenesis in 3T3‐L1 cells, mouse ear‐ and BM‐derived MSCs, and human BM‐derived MSCs. We demonstrate that the mechanism of SOST induction of adipogenesis is through inhibition of Wnt signaling in pre‐adipocytes. We also demonstrate that a decrease of sclerostin in vivo, via both genetic and pharmaceutical methods, significantly decreases bone marrow adipose tissue (BMAT) formation. Overall, this work demonstrates a direct role for SOST in regulating fate determination of BM‐adipocyte progenitors. This provides a novel mechanism for which BMAT is governed by the local bone microenvironment, which may prove relevant in the pathogenesis of certain diseases involving marrow adipose. Importantly, with anti‐sclerostin therapy at the forefront of osteoporosis treatment and a greater recognition of the role of BMAT in disease, these data are likely to have important clinical implications. Abstract : Sclerostin, a gene that encodes the SOST protein, is expressed by osteocytes within cortical and trabecular bone. We found that SOST protein can regulate bone marrow progenitor cell differentiation by not only inhibiting osteogenesis, but also inducing bone marrow adipogenesis. This novel role for sclerostin in development of bone marrow adipose suggests that sclerostin‐targeting therapies may not only increase osteogenesis, but also decrease bone marrow adipogenesis, which could have wide clinical implications.